INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Madrigal Pharmaceuticals, Inc. - MDGL
NEW YORK CITY, NY / ACCESS Newswire / November 20, 2026 /Pomerantz LLP is investigating claims on behalf of investors of Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ:MDGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Madrigal and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 3, 2026, Madrigal disclosed in its quarterly report that on October 9, 2026, the Company 's former Senior Vice President and Head of Clinical Development filed a whistleblower complaint against Madrigal alleging that he reported to Madrigal 's Senior Executive Leadership "adverse safety findings and unreproducible efficacy data" for the Company 's only approved drug, Rezdiffra-specifically, "that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with their own source data, and allowing an unblinded Board member... to control the adjudication of clinical outcomes."
On this news, Madrigal 's stock price fell $34.84 per share, or 8.08%, to close at $396.32 per share on November 3, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE:Pomerantz LLP
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.











